Form 4: Adverum Director Sells Shares, Options Post-Lilly Merger

Adverum Biotechnologies director Patrick Machado disposed of all common stock and stock options following the company's acquisition by Eli Lilly and Company.

Summary

• Patrick Machado, a director of Adverum Biotechnologies, Inc., reported changes in beneficial ownership following the company's merger with Eli Lilly and Company's subsidiary.
• The merger, effective December 9, 2025, resulted in Adverum becoming a wholly-owned subsidiary of Eli Lilly and Company.
• Adverum stockholders received $3.56 per share in cash plus one non-tradable Contingent Value Right (CVR) for each share.
• Each CVR represents the contractual right to receive up to two contingent cash payments totaling up to an aggregate of $8.91 per CVR upon the achievement of specified milestones.
• Machado disposed of 8,818 shares of common stock on December 9, 2025, resulting in zero beneficially owned shares.
• Multiple stock options with exercise prices greater than or equal to the $3.56 cash consideration were fully vested prior to the merger and then cancelled for no consideration at the effective time.
• Stock options with an exercise price less than $3.56 were automatically cancelled in exchange for cash (equal to the Cash Consideration minus the exercise price) and one CVR per share.

Sentiment

Score: 4

Explanation: The sentiment is mixed. While the merger provides an exit and potential future upside via CVRs, the company ceases to exist as an independent entity, and many options were cancelled for no value. The cash component is relatively low, with significant value tied to contingent future events.

Positives

• The merger provides a clear exit strategy and immediate cash value for Adverum shareholders.
• The inclusion of Contingent Value Rights (CVRs) offers potential upside for shareholders based on future milestone achievements, mitigating some risk of a pure cash-out.
• Adverum's integration into Eli Lilly and Company, a major pharmaceutical company, could provide stability and resources for its programs.

Negatives

• Adverum Biotechnologies, Inc. ceases to be an independent publicly traded entity, removing its stock from the market.
• Out-of-the-money stock options (those with an exercise price equal to or greater than $3.56) were cancelled for no consideration, resulting in a loss for holders of those options.
• The CVRs are non-tradable, limiting liquidity and requiring holders to wait for milestone achievements.

Risks

• The value of the CVRs is contingent on the achievement of specified milestones, which may not occur, leading to no additional payments.
• The CVRs are non-tradable, meaning holders cannot sell them for immediate value.
• The merger consideration of $3.56 per share in cash might be considered low by some investors, especially if the company's intrinsic value was perceived to be higher.

Future Outlook

Adverum Biotechnologies, Inc. is now a wholly-owned subsidiary of Eli Lilly and Company. The future outlook for the former public entity is integrated into Eli Lilly's strategic plans, with potential future payments tied to CVR milestones for former Adverum shareholders.

Management Comments

• In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025, by and among the Issuer, Eli Lilly and Company and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation, Purchaser completed a tender offer for shares of the Issuer's Common Stock.
• In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash... plus (ii) one non-tradable contingent value right (each, a 'CVR'), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR...
• After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer... effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.

Industry Context

This acquisition by Eli Lilly and Company reflects a trend of larger pharmaceutical companies acquiring smaller biotechnology firms to bolster their pipelines and intellectual property. It signifies consolidation within the biotech sector, where promising assets are often absorbed by well-capitalized industry leaders.

Comparison to Industry Standards

• The use of CVRs in biotech acquisitions is a common mechanism to bridge valuation gaps and share future development risks/rewards, similar to deals like Sanofi's acquisition of Kadmon Holdings or Bristol Myers Squibb's acquisition of MyoKardia.
• The cash component of $3.56 per share, combined with a potential $8.91 per CVR, suggests a total potential value of $12.47 per share, which would need to be compared against Adverum's historical trading prices and analyst targets prior to the merger announcement to assess its premium or discount relative to industry benchmarks for similar-stage biotech acquisitions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, losing direct equity in Adverum.
• Option Holders: Those with out-of-the-money options lost their investment; those with in-the-money options received cash and CVRs.
• Employees: Adverum employees are now part of Eli Lilly and Company, potentially impacting roles, benefits, and corporate culture.
• Customers/Partners: Operations and relationships will likely be integrated under Eli Lilly's umbrella.

Next Steps

• Monitoring the achievement of specified milestones for the Contingent Value Rights (CVRs) to determine if additional payments will be made.
• Integration of Adverum's operations and pipeline into Eli Lilly and Company.

Key Dates

Recommendation

The company has been acquired and is no longer a publicly traded entity. Shareholders who have not yet tendered their shares would effectively be forced to sell them at the merger price (cash + CVRs) as the company is now a wholly-owned subsidiary. Therefore, the recommendation is to sell or acknowledge the completed sale as the stock is no longer independently tradable.

Keywords

Adverum Biotechnologies, ADVM, Eli Lilly, Merger, Acquisition, Form 4, Insider Trading, Contingent Value Rights, CVR, Stock Options, Tender Offer, Biotechnology, Pharmaceuticals